Chest pain, breathlessness at rest or sudden swelling need emergency care. Call 911.
The letters answer a different question from the one most people ask first. They do not describe how bad someone feels on a given day. They describe where the heart sits on a path that begins long before the first symptom, which is why a person can be staged at A with a completely normal heart scan.
Heart failure is a clinical syndrome in which symptoms and signs are caused by a structural or functional abnormality of the heart, supported by objective evidence of congestion such as raised natriuretic peptides or imaging findings 1.
The word congestive points at the fluid side of the problem. When the heart cannot move blood forward at normal filling pressures, pressure builds behind it. Pressure backing up into the lungs produces breathlessness, first on exertion and later lying flat. Pressure backing up through the veins produces swollen ankles, a heavy abdomen, visible neck veins and weight that climbs over a few days rather than a few months 2.
The body does not sit still while this happens. Hormonal and nervous system responses push the kidneys to hold salt and water and tighten blood vessels, which supports blood pressure in the short term and adds to congestion over the longer term 2. That loop is one reason heart failure is described as progressive rather than static.
It is also worth being clear about what heart failure is not. It is not the heart stopping, and it is not a single disease with a single cause. It is the shared end point of many different problems, including long-standing high blood pressure, damage after a heart attack, valve disease, inherited cardiomyopathies and rhythm disorders. The stage describes progression along that shared path. The cause underneath it still has to be identified separately, and that work belongs to a clinician.
The letters exist because clinicians needed a way to describe disease progression that does not swing around with how a person feels this week. Stages A to D track the structural and biological journey. A separate functional classification, graded from class I to class IV, describes how much ordinary activity is limited right now 3.
Those two systems are easy to confuse, and mixing them up causes real misunderstanding. Someone can be at Stage C and feel well, with almost no limitation on a good month. Someone else can be at the same stage and struggle to cross a room. Functional class moves up and down. The letter is designed to move in one direction only.
The current consensus definition frames the same path in plain words, describing people as at risk, pre heart failure, heart failure, and advanced heart failure 1. The wording is friendlier than the letters, and the boundaries are the same.
There is one more distinction worth holding onto. Acute heart failure refers to a rapid onset or rapid worsening of symptoms that needs urgent assessment, and it can be the first presentation in someone not previously diagnosed or a decompensation in someone with known chronic heart failure 4. Acute and chronic describe timing. The letters describe progression. They are answering different questions.
Stage A means a person is at risk of heart failure but has no structural heart abnormality, no symptoms and no abnormal cardiac blood markers 1. The heart, on current testing, looks normal.
The risk comes from everything around the heart. Long-standing high blood pressure, type 2 diabetes, obesity and metabolic dysfunction, known coronary artery disease, a family history of cardiomyopathy and past exposure to cardiotoxic agents all place someone in this group.
Stage A exists for one reason. It marks the window where the trajectory is most open to change, before muscle has thickened, before a chamber has stretched and before the kidneys have started compensating. Nobody at Stage A feels anything, which is precisely the difficulty. The only way to know you are in this group is to look at the risk factors and the numbers.
What tends to get monitored here is unglamorous and useful. Blood pressure over time rather than at a single appointment. Glucose control. Kidney function. Lipids. Body composition. None of that is specific to the heart, and all of it feeds the pressure and volume load the heart handles every day. Whether anything should change in response to those numbers is a decision for a clinician who knows the whole picture.
Stage B means there is evidence of structural or functional heart abnormality, or persistently raised cardiac blood markers, but the person has never had symptoms of heart failure 1. It is often called pre heart failure.
The findings that place someone here are concrete. A reduced ejection fraction on an echocardiogram. A thickened left ventricular wall. An enlarged chamber. Significant valve disease. A previous heart attack. Persistently elevated natriuretic peptides or cardiac troponin in the absence of another explanation also counts, which is one of the few situations where a blood test alone can move someone from one stage to the next 1.
The mechanism behind Stage B is remodelling. Under sustained pressure or volume load, or after muscle is lost, the heart changes shape and composition. Walls thicken, chambers widen, scar tissue replaces some muscle. The heart compensates well enough that nothing feels wrong, and that silence is the defining feature of this stage.
Most Stage B findings turn up by accident, on a scan ordered for another reason, on a routine electrocardiogram, or on a blood test taken during an unrelated workup. That is the practical argument for testing in people who sit at Stage A with several risk factors. An observation at Stage B does not mean symptoms are coming. It means the question of what is driving the change is now worth answering, with a clinician, rather than later.
Stage C means there is structural heart disease together with current or previous symptoms of heart failure 1. This is the stage most people picture when they hear the diagnosis.
The symptoms follow the congestion. Breathlessness on exertion that was not there a year ago. Breathlessness lying flat, so an extra pillow creeps into the bed. Waking at night short of breath. Swollen ankles or legs that leave a dent under a thumb. Abdominal fullness or early satiety. Fatigue that is out of proportion to the day. Weight climbing by a couple of kilograms across a few days, which reflects fluid rather than fat.
One point about Stage C surprises people. Once someone has reached it, they stay there even after symptoms settle completely. A person whose breathlessness resolves and whose ejection fraction improves is still described as Stage C, because the staging records the history of the disease rather than today's status. Their functional class may now be class I. The letter does not go back to B.
Stage C is where monitoring becomes routine, with care teams commonly tracking weight, symptoms, blood pressure, kidney function and electrolytes over time. What is done with that information, including any change in management, is decided by a licensed provider who knows the case.
Stage D describes advanced heart failure, where severe symptoms occur at rest or on minimal exertion and persist despite management that has been optimised 1.
The markers of this stage are more about pattern than about any single number. Repeated unplanned hospital admissions for congestion. Symptoms that return quickly after each admission. Progressive kidney or liver involvement driven by chronic congestion and low forward flow. Unintended weight loss and muscle wasting. An inability to tolerate the management previously in place. Episodes of acute decompensation that need urgent hospital care sit alongside this picture 4.
Stage D is a signal for specialist referral rather than a prediction. It means the problem has outgrown routine outpatient management and needs a team that handles advanced heart failure day to day, including a careful review of what is driving the decline. Treatment decisions belong to a licensed provider, and at this stage they usually belong to a specialist team rather than a single clinician.
Ejection fraction answers what type of heart failure is present, while the letter answers how far it has progressed. A person has both labels at once, for example Stage C heart failure with preserved ejection fraction.
Ejection fraction is the proportion of blood in the left ventricle pushed out with each beat, measured on an echocardiogram. The categories below are the ones used in current classification 5.
| Category | Left ventricular ejection fraction | What it describes |
|---|---|---|
| Reduced ejection fraction (HFrEF) | 40% or lower | The ventricle empties poorly, often after muscle damage or dilation |
| Mildly reduced ejection fraction (HFmrEF) | 41 to 49% | An intermediate group that can move in either direction over time |
| Preserved ejection fraction (HFpEF) | 50% or higher | Pumping looks normal, but a stiff ventricle fills poorly at normal pressures |
| Improved ejection fraction (HFimpEF) | Previously 40% or lower, now above 40% with an improvement of at least 10 points | Pumping has recovered, though the heart failure history stands |
These categories are not cosmetic. They shape which investigations come next and which management pathways a clinician considers. They also explain why a normal ejection fraction never rules heart failure out. In preserved ejection fraction, the squeeze is fine and the filling is the problem, so pressures rise and congestion develops with an echocardiogram that reads normal at first glance.
The natriuretic peptides, BNP and NT-proBNP, are the blood tests used most directly in heart failure assessment, and they inform diagnosis, staging and prognosis.
Research suggests that, in heart failure, these peptides are released by heart muscle as wall stress and filling pressures rise, which is why their concentration tracks the degree of cardiac strain and why they are used to support or question a diagnosis when breathlessness is unexplained 6. The current consensus definition includes raised natriuretic peptides among the objective findings that corroborate heart failure 1. If you want the detail on how the test is run and what influences a result, the guide on what is a bnp blood test covers it.
Interpretation needs context. Age, kidney function, body weight and atrial fibrillation all shift natriuretic peptide concentrations, and obesity tends to lower them, so the same number can carry a different meaning in two different people 6. Thresholds also differ by assay and by whether the setting is acute or outpatient, which is why a result should be read against the laboratory's own reporting rather than a number remembered from somewhere else.
Cardiac troponin is the other widely used marker. Studies indicate that detectable or persistently elevated troponin in chronic heart failure reflects ongoing myocardial injury and carries prognostic information beyond the diagnosis itself 7.
Here is the honest limit. No blood test prints a letter. A raised natriuretic peptide is an observation. It may reflect cardiac strain, and it may reflect kidney impairment, older age or a rhythm problem instead. The next step is an echocardiogram and a clinical assessment, not a conclusion.
Sodium measures the concentration of sodium in the blood, which reflects the balance between sodium and water rather than how much salt is in the diet. In heart failure, the hormonal response that holds onto water can dilute blood sodium, so a low result is a finding clinicians pay attention to.
FitScript's optimal range for sodium is 138 to 142 mEq/L, against a typical lab reference range of 136 to 145 mEq/L. Optimal ranges are optimization targets, not diagnostic cut-offs, and reference ranges vary by laboratory, age and sex. A result outside the standard range is worth discussing with a clinician promptly rather than watching at home. Testing detail and interpretation live on the Sodium page.
The markers that matter alongside natriuretic peptides are the ones describing the organs that share the load with the heart, mainly the kidneys, the blood and the metabolic system.
Kidney function tests, including creatinine and estimated filtration rate, matter twice over, because reduced kidney function raises natriuretic peptide levels independently and because the heart and kidneys decline together in many people. Electrolytes including potassium belong in the same panel. Haemoglobin and iron studies such as ferritin and transferrin saturation are checked because anaemia and low iron are common in heart failure and both affect exercise capacity. Thyroid markers, HbA1c, lipids and liver enzymes fill in the metabolic and congestion picture.
Beyond those routine tests, a wider set of cardiac biomarkers is used to describe injury, fibrosis and inflammation, including cardiac troponin, soluble ST2 and galectin-3, each reflecting a different part of the process rather than a single global score 7. A multi-marker approach may help refine prognostic assessment beyond natriuretic peptides alone, though no combination replaces clinical evaluation and imaging 8.
This is the reason broad, repeated testing is more informative than a single marker checked once. FitScript tests 150+ biomarkers per year and Atlas, FitScript's AI health advisor, interprets the pattern across them, while any treatment decision belongs to a licensed provider.
The stage is assigned by combining three things, the risk factors present, what imaging shows about heart structure and function, and whether symptoms of heart failure have ever occurred. No single test produces the letter.
In practice the assessment starts with history and physical examination, looking for breathlessness patterns, exercise tolerance, swelling, raised neck veins and lung findings, and continues with an electrocardiogram, chest imaging, natriuretic peptide measurement and an echocardiogram 3.
The echocardiogram does the heaviest lifting. It gives ejection fraction, chamber sizes, wall thickness, valve function and estimates of filling pressure, which is what separates Stage A from Stage B in someone with no symptoms. Blood tests then add biological confirmation and context, and they can be repeated far more easily than imaging, which makes them useful for tracking.
The practical takeaway for a reader is that getting staged is not a mystery process. It is a structured assessment, and the main thing that delays it is not seeking an explanation for a symptom that developed slowly enough to be blamed on age or fitness.
The letters are built to move in one direction, so a person does not return from Stage C to Stage B, even when symptoms and heart function improve substantially.
What can improve is almost everything a person experiences. Functional class can move from III back to I. Ejection fraction can recover, and recovery is recognised formally as heart failure with improved ejection fraction, where a previously reduced ejection fraction rises above 40% with a meaningful absolute increase 5. Natriuretic peptide concentrations can fall as filling pressures come down 6. The consensus definition describes these trajectories explicitly, including periods where someone with a heart failure history is free of symptoms and signs 1.
The reason the letter stays put is that improvement is not the same as erasure. The underlying structural change and the risk of decompensation remain, so the staging keeps the history visible and keeps the monitoring in place. Reading a stable letter as failure, when symptoms and numbers have improved, misreads what the system is for.
Progression is shaped mostly by the load placed on the heart over years and by how well the drivers underneath are controlled, not by anything the heart does on its own.
The usual contributors are the familiar ones. Blood pressure that stays high for long periods. Poor glucose control. Body composition and visceral fat. Alcohol intake. Sleep-disordered breathing. Iron deficiency and anaemia. Declining kidney function. Ongoing coronary disease. Arrhythmias, particularly atrial fibrillation, which both reduce filling efficiency and raise natriuretic peptide levels.
Separately, there are triggers that cause an abrupt step down rather than slow drift. Infections, uncontrolled rhythm problems, a new ischaemic event and sharp increases in salt and fluid load are typical precipitants of an acute episode requiring urgent assessment 4. Someone can be stable for a year and decompensate inside a week.
What is worth noting is how many of these items are measurable before they cause trouble, and how few of them announce themselves. Blood pressure, HbA1c, iron status, kidney markers and natriuretic peptides are all numbers rather than symptoms. Checking them on a schedule is how a slow drift gets noticed, and what to change in response is a clinician's call.
In people with heart failure, how long and how well someone lives depends heavily on which stage the condition is caught at, how tightly the underlying drivers are controlled and how consistently the picture is monitored over time.
Biomarkers carry part of that information. Higher natriuretic peptide concentration is associated with worse outcomes in heart failure, which is why the test is used for risk assessment and not only for diagnosis 6. Markers of myocardial injury and fibrosis add further prognostic detail beyond symptoms alone 7, and combining several markers may help describe risk more completely than any one of them 8.
Two cautions belong with that. A prognostic marker describes a group, not an individual, and a single elevated number on one morning is not a forecast. And the trend across repeated measurements usually says more than any isolated value, which is another argument for testing on a schedule rather than only during a crisis.
The practical version is simple enough. Earlier detection means more of the trajectory is still open. That is why the staging system bothers to include people whose hearts are still normal, and why the most useful thing a reader at Stage A or Stage B can do is get the relevant numbers measured and reviewed with a clinician.
Any new or worsening breathlessness, swelling or exercise intolerance deserves a clinical assessment rather than a wait-and-see approach, and some patterns need care the same day.
Chest pain, breathlessness at rest, breathlessness that wakes someone at night, coughing pink frothy sputum, fainting, a racing or irregular heartbeat with light-headedness, or sudden swelling all need emergency care. Call 911. Rapid onset or rapid worsening of heart failure symptoms is an acute presentation requiring urgent evaluation 4.
Book a non-urgent appointment for breathlessness on exertion that is new over weeks or months, ankle swelling that returns daily, weight climbing by a couple of kilograms across a few days, needing extra pillows to sleep comfortably, or fatigue that does not fit the week. Bring any recent blood results with you, and mention risk factors such as high blood pressure, diabetes or a family history of cardiomyopathy.
A laboratory result sitting outside the standard range is worth discussing with a clinician promptly, and it should never be ignored because it looks mild. This page is educational and is not medical advice. Discuss your results and any treatment with a clinician or licensed provider, who decides what, if anything, should change.
Stage A means risk factors are present but the heart is structurally normal and there are no symptoms. Stage B means there is structural change or an abnormal cardiac blood marker, still without symptoms. Stage C means structural heart disease with current or past symptoms, and Stage D means severe symptoms that persist despite management that has already been optimised. A clinician assigns the stage using history, imaging and blood tests together.
Yes, and that is the point of the stage. Stage A describes people with risk factors such as high blood pressure, type 2 diabetes, obesity or a family history of cardiomyopathy, whose heart scan and cardiac markers are normal. Nothing is felt at this stage, so it is identified through measurement rather than symptoms.
No. Stage C simply means symptoms have occurred at some point alongside structural heart disease, and many people at Stage C have mild or well-controlled symptoms. Advanced heart failure is Stage D, where symptoms are severe at rest or on minimal exertion despite full management. Your clinician can tell you which stage applies to your situation.
A low natriuretic peptide result makes heart failure a less likely explanation for unexplained breathlessness, but no single blood test confirms or excludes it. Age, kidney function, body weight and heart rhythm all affect the number, and thresholds differ between laboratories and assays. A clinician reads the result alongside the examination and an echocardiogram before drawing any conclusion.
Blood sodium reflects the balance between sodium and water in the body rather than how much salt is eaten. When the body holds onto extra water, the sodium concentration can fall, so a low value is something clinicians look at closely in this context. A result outside the standard reference range is worth discussing with a clinician promptly.
The letters are designed to move in one direction only, so the stage stays where it is even when things improve. What can improve is symptoms, exercise tolerance, pumping function and blood marker levels, and that improvement is recognised separately. Keeping the stage unchanged is a way of keeping the history and the monitoring visible.
Ejection fraction describes the type of heart failure, based on how much blood the left ventricle pushes out with each beat, and it is grouped as reduced, mildly reduced, preserved or improved. The stage describes how far the condition has progressed. A person carries both labels at the same time, for example Stage C with preserved ejection fraction.
Chest pain, breathlessness while at rest, sudden swelling, fainting, coughing pink frothy sputum, or a racing heartbeat with light-headedness all need emergency care. Call 911 rather than waiting for a scheduled appointment. Slower changes such as new breathlessness on exertion or ankle swelling that returns daily still need review, but through a routine appointment.